Health Care Analysis 28 (2):121-136 (2020)

The most common solutions to the problem of high pharmaceutical prices have taken the form of regulations, price negotiations, or changes in drug coverage by insurers. These measures for the most part transfer the burden of drug expenditures between pharmaceutical companies and payers or between payers. The aim of this study is to propose an alternative model for the relationship between the main stakeholders involved in the price setting and purchasing of pharmaceuticals, one that encourages a more cooperative approach. We draw from principles of ethics and health economics and apply them to the context of the pharmaceutical industry. The model prioritises two objectives, to make drugs financially accessible to the patients who need them, and to keep pharmaceutical companies viable and profitable. It is centered around the sharing of financial risk between the main stakeholders, which we describe as ‘enlightened risk sharing’. After establishing the foundations of this model, we expand on the type of policies that can follow these principles with current day examples.
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1007/s10728-020-00394-x
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 58,954
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

The Corporation as a Moral Person.Peter A. French - 1979 - American Philosophical Quarterly 16 (3):207 - 215.
The Right to a Decent Minimum of Health Care.Allen E. Buchanan - 1984 - Philosophy and Public Affairs 13 (1):55-78.
Priceless Goods: How Should Life-Saving Drugs Be Priced?Ian Maitland - 2002 - Business Ethics Quarterly 12 (4):451-480.
Priceless Goods: How Should Life-Saving Drugs Be Priced?Ian Maitland - 2002 - Business Ethics Quarterly 12 (4):451-480.
On Personal Responsibility and the Human Right to Healthcare.Yvonne Denier - 2005 - Cambridge Quarterly of Healthcare Ethics 14 (2):224-234.

View all 8 references / Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Ethics, Pricing and the Pharmaceutical Industry.Richard A. Spinello - 1992 - Journal of Business Ethics 11 (8):617 - 626.


Added to PP index

Total views
4 ( #1,220,936 of 2,427,259 )

Recent downloads (6 months)
2 ( #346,009 of 2,427,259 )

How can I increase my downloads?


My notes